PledPharma AB (publ) Stock Nasdaq Stockholm
Equities
SE0003815604
Biotechnology & Medical Research
Sales 2024 * | 65.08M 5.98M | Sales 2025 * | 471M 43.26M | Capitalization | 1.83B 168M |
---|---|---|---|---|---|
Net income 2024 * | -291M -26.73M | Net income 2025 * | 105M 9.64M | EV / Sales 2024 * | 29.7 x |
Net Debt 2024 * | 103M 9.43M | Net cash position 2025 * | 61.97M 5.69M | EV / Sales 2025 * | 3.76 x |
P/E ratio 2024 * |
-6.59
x | P/E ratio 2025 * |
9.16
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 72.61% |
Latest transcript on PledPharma AB (publ)
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 48 | 17-06-15 | |
Yilmaz Mahshid
DFI | Director of Finance/CFO | 45 | 17-12-30 |
Chief Tech/Sci/R&D Officer | - | 22-05-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jacques Näsström
CTO | Chief Tech/Sci/R&D Officer | 65 | 10-06-23 |
Mats Blom
BRD | Director/Board Member | 59 | 21-03-31 |
Director/Board Member | 50 | 19-12-31 |
1st Jan change | Capi. | |
---|---|---|
+2.49% | 96.73B | |
-0.32% | 21.31B | |
-16.61% | 21.21B | |
-5.20% | 18.79B | |
-42.14% | 16.37B | |
-27.40% | 13.68B | |
+1.44% | 13.44B | |
+21.29% | 10.98B | |
-21.79% | 8.56B |